| HONORS:
Phi Beta Kappa, Amherst College, 1980;
Frank Dow Award in Chemistry, Amherst College, 1980;
Logan Clendenning Fellowship in the History of Medicine, 1982;
George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997;
The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994 |
|
| Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) NS24778 | NINDS, NIH 11/89-4/94 | Medical Director and Steering Committee member |
|
| Dideoxyinosine treatment of AIDS Dementia | Industry Sponsored Clinical Trial 10/90-11/91 | Principal Investigator |
|
| Parkinson Study Group START Clinical Trials | Industry Sponsored 11/1/90-4/30/92 | Medical Director and Steering Committee member |
|
| AIDS Clinical Trial Group | National Institute of Allergy and Infectious Disease, NIH | Member, Neurology Core Committee 7/90-7/94, 2UO1AI27658 |
|
| Parkinson Study Group ROADS Clinical Trial | Industry Sponsored | Medical Director and Steering Committee member 4/92-4/94 |
|
| BLIND-DATE Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 3/93-1/95 |
|
| Glutamate Antagonist Tolerability in Huntington's Disease | Industry Sponsored Clinical Trial | Principal Investigator 7/1/93-6/30/94 |
|
| STEP-UP Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 10/93-6/95 |
|
| European Network for Striatal Transplantation in Huntington's Disease(NEST-HD):preclinical development & clinical trial method | European Economic Community | Sub-proposer and Consultant |
|
| Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, David Clifford, PI) | NINDS, NIH | Site Principal Investigator 12/1/93-11/30/95 |
|
| SEESAW Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 11/93-12/95 |
|
| Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders | Co-Principal Investigator (L Epstein PI) 1/94-12/96 |
|
| A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy | AIDS Clinical Trials Group, Protocol 242, 2/94-2/96 | Study Chair |
|
| Clozapine for Psychosis in PD | FDA, Orphan Drug Div. | Medical Director (J Friedman PI) 7/94-6/97 |
|
| Investigation of Tolerability of OPC-14117 in Huntington's Disease | Otsuka Pharmaceuticals | Medical Director (I Shoulson PI) 9/94-9/95 |
|
| Trial of a Glutamate Antagonist in PD and MSA | Industry Sponsored | Principal Investigator 9/95-9/96 |
|
| Evaluation of SPECT Imaging in The Diagnosis of PD | Industry Sponsored | Director of Coordination Center (K Marek PI) 9/95-9/96 |
|
| Comparison of Levodopa and a Dopamine Agonist in PD | Industry Sponsored | Director of Coordination Center (I Shoulson PI) 10/95-10/02 |
|
| PSG PRIME: Study of a Dopamine Agonist in Minority Persons | Industry Sponsored | Director of Coordination Center (C Tanner PI) 10/95-3/97 |
|
| TACT Study: Treatment of ADHD in Children with Tourette's | NIH NINDS, RO1 NS33654 | Director of Coordination Center (R Kurlan, PI) 7/96-7/99 |
|
| PSG SPIRAL Study: Interaction Study of Remacemide and Levodopa in Parkinson's Disease | Industry Sponsored | Principal Investigator 10/96-11/97 |
|
| Clinical Trials Unit in HIV Dementia | NINDS, NIH, P01 NS32228 | Project PI (D Clifford, U of Washington, PPG PI) 12/93-4/02 |
|
| Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease | NIH, RO1 NS35284 | Principal Investigator 5/97-5/01 |
|
| Neurocognitive Function, HIV Load and Surrogate Markers (NEAD) | NIH, P01 NS36519-01A1 | Data Management Core Director (L Epstein PI) 2/98-1/03 |
|
| Earlier vs. Later L-dopa in Parkinson's Disease | NIH, R01 NS34796-01A1 | Coordination Center Director (S Fahn PI) 6/98-6/01 |
|
| Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease | NIH R01 NS36714 | Co-Principal Investigator (C Shults PI) 6/98-6/01 |
|
| Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | Principal Investigator 1/99-12/04 |
|
| ERSET: A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy | NIH, NS37897 | Coordination Center Director (J Engel PI) 7/99-6/07 |
|
| Alzheimer's Disease Cooperative Study | 5U01-AG010483 | Chair, Safety Monitoring Committee (L Thal, PI) 9/01-6/12 |
|
| PSG PATCH Study: Topical Dopamine Agonist in PD | Industry Sponsored | Coordination Center Director 6/99-12/00 |
|
| PSG RAPID Study: Monoamine Oxidase Inhibitor in PD | Industry Sponsored | Coordination Center Director 10/97-10/00 |
|
| Ethylester of Levodopa in PD | Industry Sponsored | Coordination Center Director 6/99-6/02 |
|
| Early Randomized Surgical Epilepsy Trial | NIH R21 NS42372 | Coordination Center Director (J Engel PI) 7/01-6/06 |
|
| Targeted Neuroprotection for HIV-1 Associated Neurologic Disease | NIH PO1 MH64570 | Project Co-PI (H Gelbard PI) 7/01-6/05 |
|
| Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | Principal Investigator 9/01-7/06 |
|
| Neurobiological Predictors of Huntington's Disease (PREDICT-HD) | NINDS NS40068 | Coordination Center Director (J Paulsen PI) 11/01-10/06 |
|
| Prospective Huntington At-Risk Observational Study (PHAROS) | Huntington's Disease Society of America & Hereditary Disease Fdn | Coordination Center Director (I Shoulson, PI) 5/99-12/01 |
|
| Prospective Huntington At-Risk Observational Study (PHAROS) | NIH / NHGRI / NINDS R01HG02449 | Coordination Center Director (I Shoulson, PI) 9/30/02-6/30/07 |
|
| HSG Trend Study: A multicenter placebo-controlled efficacy and safety trial of an experimental membrane-stabilizing drug | ethyl-EPA in ambulatory Huntington's Disease patients | Coordination Center Director (I Shoulson, PI) 3/05-6/08 |
|
| HSG DOMINO Study: Double blind study of minocycline in Huntington's disease | FD-R-02588 | Coordination Center Director (M Cudkowicz, PI) 8/05-8/08 |
|
| Multi-Center Phase 1-2A Open-Label Dose-Escalation & Randomized, Double-Blind, Placebo-controlled Study of Dimebon in Subjects | w/ HD (DIMOND) Industry Sponsored | Principal Investigator 2/06-5/07 |
|
| PSG Prami BID Study: A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole in subjects w/ PD | Industry Sponsored | Principal Investigator 3/1/06-1/08 |
|
| The University of Rochester's Clinical and Translational Science Institute | UL1 RR024160, KL2 RR024136, TL1 RR024135 | Instructor (T Pearson, PI) 9/06-6/11 |
|
| Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | Principal Investigator 12/1/06-11/30/11 |
|
| Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | Principal Investigator 1/99-12/04 |
|
| Data Coordination and Biostatistics Center for the NORDIC Network | National Eye Institute, 1U10 EYO17387-01A1 | Principal Investigator 02/10/09 – 01/31/14 |
|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate | Huntington Disease (HORIZON): Medivation | Principal Investigator 3/15/09-3/15/11 |
|
| A multi-center, N.A., randomized, double-blind, parallel group study comparing three doses of ACR16... (HART) | NeuroSearch Sweden AB | Principal Investigator 11/1/07-3/31/10 |
|
| Inosine for Parkinson's Disease: Safety and Trial Design Optimization | Michael J. Fox Foundation Rapid Response Innovation Award | Principal Investigator, Data Coordination Ctr 2/15/08-2/14/12 |
|
| Coordination and Statistics for CoQ10 in HD (2CARE) | NIH NINDS RO1 NS052619 | Co-Principal Investigator (M McDermott, PI) 9/1/05-8/30/09 |
|
| Prophylactic Phenobarbital after Resolution of Neonatal Seizures (PROPHENO) | NICHD, RO1 HD057977 | Steering Committee (R Guillett, PI) 12/01/2008 – 11/30/2013 |
|
| Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions | Michael J. Fox Foundation Rapid Response Innovation Award | Principal Investigator 11/07-05/08 |
|
| PSG PRECEPT study, CEP1347 in Early PD | Industry Sponsored | Coordination Center Director (I Shoulson, PI) 12/01-8/04 |
|
